SecProbe.io

CORRESP
 1
 filename1.htm

 Sidley
 Austin LLP
 787
 Seventh Avenue
 New
 York, NY 10019
 +1
 212 839 5300
 +1
 212 839 5599 Fax

 AMERICA
 • ASIA
 PACIFIC • EUROPE

 Via EDGAR

 United States Securities and Exchange Commission

 Division of Corporation Finance

 Office of Life Sciences

 100 F Street, N.E.

 Washington, D.C. 20549-3628

 Attention: Jessica Dickerson

 Re: GlycoMimetics, Inc.

 Registration Statement on Form S-4

 Filed February 18, 2025

 File No. 333-285035

 Ladies and Gentlemen,

 On behalf of GlycoMimetics, Inc. (the " Company "),
we are submitting this letter to the Securities and Exchange Commission (the " SEC ") via EDGAR in response to the comment
letter from the staff of the SEC (the " Staff "), dated March 17, 2025, pertaining to the Company's above-referenced
Registration Statement on Form S-4 (the " Registration Statement "). In connection with such responses, the Company
is concurrently filing Amendment No. 1 to the Registration Statement (the " First Amended Registration Statement ").

 For your convenience, the Staff's comments
are summarized in this letter, and each comment is followed by the applicable responses on behalf of the Company. Unless otherwise indicated,
page references in the responses correspond to the page numbers in the First Amended Registration Statement. Capitalized terms
used in this letter but otherwise not defined herein shall have the meanings set forth in the First Amended Registration Statement.

 Registration Statement on Form S-4

 Cover Page

 1. As required by Item 501(b)(2) of Regulation S-K, as referenced in Item 1 of Form S- 4,
please disclose the amount of securities being offered.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on the Cover
Page and page iv of the First Amended Registration Statement in response to the Staff's comment.

 Securities and Exchange
Commission

 April 4, 2025

 Page 2

 2. You state that your shares are currently listed on Nasdaq and that it is a waivable condition to
the consummation of the merger that the combined company is approved for listing on Nasdaq. Given this condition, please clarify here
that you are currently not in compliance with the Nasdaq listing requirements. In addition, given that this condition is waivable, please
revise your disclosure to indicate whether recirculation or re-solicitation of stockholders will occur prior to the closing if the listing
application is not approved but the condition is waived. If stockholders will not have certainty regarding the listing of the combined
company's shares at the time they are asked to vote, please clarify this fact here and elsewhere in the proxy statement/prospectus
as appropriate. Please also provide risk factor disclosure that addresses the potential consequences of the parties waiving the condition
and the closing occurring without the Nasdaq listing, including but not limited to the liquidity implications thereof.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on the Cover
Page and pages viii, ix, 15, 18, 19 and 149 of the First Amended Registration Statement in response to the Staff's comment.

 Questions and Answers about the Merger

 What is the Merger?, page iii

 3. Please disclose the number of shares of common stock you expect to issue, or otherwise reserve for
issuance, in connection with the merger. In your disclosure, separately state the number of shares you expect to underlie shares of the
Series A Preferred Stock and pre-funded warrants to be issued upon consummation of the merger.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on the Cover
Page and page iv of the First Amended Registration Statement in response to the Staff's comment.

 What proposals will be voted on at the GlycoMimetics
Special Meeting in connection with the Merger?, page v

 4. You state that Proposal No. 2 must be approved to have an adequate number of authorized but
unissued shares of common stock to complete the merger. Please disclose the number of additional authorized shares you expect to need
to complete the merger and disclose the number of authorized shares that will be available for issuance after factoring in the number
of shares to be issued in connection with the merger if this proposal is approved.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on page vi
of the First Amended Registration Statement in response to the Staff's comment.

 Securities and Exchange
Commission

 April 4, 2025

 Page 3

 What proposals are to be voted on at the
GlycoMimetics Special Meeting, other than the Nasdaq Issuance Proposal..., page vi

 5. We note that Proposal No. 4 is a proposal to elect directors. Given the inclusion of this proposal,
please tell us why you have not also included an advisory proposal in the proxy statement/prospectus for stockholders to approve executive
compensation pursuant to Exchange Act Rule 14a-21(a). Alternatively, revise the proxy statement/prospectus to include such proposal.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on the
Cover Page and pages vii, 6, 109, 110, 111, and 252 of the First Amended Registration Statement in response to the
Staff's comment.

 If my GlycoMimetics shares are held in "street
name" by my broker..., page ix

 6. You state that if a beneficial owner does not instruct such owner's broker, bank or other
agent how to vote such owner's shares, the broker, bank or other agent may still be able to vote such shares in its discretion.
Please disclose for which of the proposals brokers, banks and other agents will be able to vote shares in the absence of instructions
from the respective beneficial owner.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on pages xii
and 112 of the First Amended Registration Statement in response to the Staff's comment to further explain and clarify the impact
of a broker non-vote, if any, on each proposal. The Company believes that the revised disclosure includes the information required pursuant
to Item 21(b) of Schedule 14A, which requires identifying the "treatment and effect under applicable state law and registrant
charter and bylaw provisions of … broker non-votes" but does not require disclosure of the proposals over which brokers,
banks and other agents will and will not have discretionary voting authority.

 Prospectus Summary

 The Companies

 Crescent, page 1

 7. Revise your summary of Crescent to disclose the following:

 · that Crescent was founded in September 2024 and launched to research and develop antibody and
ADC candidates from Paragon Therapeutics, Inc., an antibody discovery engine founded by Fairmount Funds Management LLC;

 · that Crescent does not yet have any product candidates but, instead, has unexercised options under
the Paragon Option Agreements to license the CR-001 and CR-002 product candidates from Paragon;

 · identify Paragon, Fairmount and Parascent as related parties;

 Securities and Exchange
Commission

 April 4, 2025

 Page 4

 · disclose, if true, that Crescent does not currently have any in-house development capabilities and
that Paragon has launched other companies with intellectual property or assets that Paragon has developed in-house;

 · clarify if Crescent would be entitled to any improvements on CR-001 and CR-002 that Paragon develops,
or if Paragon could grant the rights to any such improvements, or to any new and competing technologies, to other companies against which
Crescent would compete, and include risk factor disclosure as appropriate; and

 · include a cross reference to a more fulsome discussion of Crescent's relationship, and the
nature of these arrangements, with Paragon.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on page 2
and throughout the First Amended Registration Statement in response to the Staff's comment.

 8. Given that Crescent was recently formed in September 2024 and that it has not yet exercised
any options under the Paragon Option Agreements, please revise your disclosure here and throughout the proxy statement/prospectus as appropriate
to clarify the current state of Crescent's business. For example, if Crescent is not yet "developing" product candidates
and has not yet exercised its option for CR-001, you might clarify that Crescent "intends to develop" or "is collaborating
with Paragon to develop" or "to advance" product candidates and that it "expects" CR-001 to be its initial
product candidate, subject to Crescent's exercise of the option and entry into the respective license agreement.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on pages
iii, 1, 2, 58-59, 65, 70, 272-274, 281, 283, 322, 332, 351 and F-46 of the First Amended Registration Statement in response to the
Staff's comment.

 9. We note your statement that Crescent believes the emerging data from the clinical development of
ivonescimab allows for the acceleration of the development of CR-001. Please provide a more detailed explanation of why you believe the
development of ivonescimab will allow you to accelerate the development of CR-001, a new molecular entity. We further note your statement
that Crescent plans to "systematically" seek regulatory approvals for CR-001 to treat multiple solid tumor indications. Please
clarify what you mean by "systematically" seeking regulatory approvals, and balance these statements with the fact that Crescent
has not yet begun clinical development of CR-001, that there is no guarantee Crescent will be able to accelerate development of CR-001
and that it will be several years before Crescent will be able to commercialize CR-001 if it is able to successfully complete clinical
trials and obtain the requisite regulatory approvals.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on page 1,
67, 272, 273, 277, 290, and 322 of the First Amended Registration Statement in response to the Staff's comment.

 Securities and Exchange
Commission

 April 4, 2025

 Page 5

 10. To the extent known, please disclose if and when Crescent expects to exercise its options for CR-001
and CR-002. In addition, briefly describe the influence, if any, that Fairmount and Paragon may have over any decision to exercise the
options and in negotiating the terms of the respective licensing agreements. In this regard, in addition to the relationship between Crescent,
Paragon, Fairmount and Parascent, we note your Chief Executive Officer's affiliation with Fairmount and the rights of preferred
stockholders to elect directors.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on
pages iii, 1, 2, 58, 59, 272, 273, 281, 283, 322, 332, 351 and F-46 of the First Amended Registration Statement in response
to the Staff's comment. The Company respectfully advises the Staff that, effective as of March 17, 2025, Crescent
replaced its Chief Executive Officer with an individual not affiliated with Fairmount.

 Risk Factors, page 16

 11. We note from Section 11.1 of the Merger Agreement that the representations and warranties of
the parties contained in the Merger Agreement do not survive the closing and that there are no indemnification rights. Please include
appropriate risk factor disclosure.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on pages 24
and 25 of the First Amended Registration Statement in response to the Staff's comment.

 The Special Meeting in Lieu of Annual Meeting
of GlycoMimetics Stockholders Solicitation of Proxies, page 98

 12. We note that you have retained Innisfree M&A Incorporated as your proxy solicitor. Please disclose
the material features of any contract or arrangement for such solicitation and the cost or anticipated cost thereof. Refer to Item 4(a)(3) of
Schedule 14A.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on page 113
of the First Amended Registration Statement in response to the Staff's comment.

 Anticipated Accounting Treatment, page 130

 13. You disclose that you expect to account for the merger as a reverse recapitalization. Revise this
section as well as your disclosures on pages 13 and 290 to address the following:

 · Disclose the extent to which you have determined that, immediately before the merger, GlycoMimetics
will have no or nominal operations.

 Securities and Exchange
Commission

 April 4, 2025

 Page 6

 · Disclose the extent to which you have determined that, immediately before the merger, GlycoMimetics
will have no or nominal assets, assets consisting solely of cash and cash equivalents, or assets consisting of any amount of cash and
cash equivalents and nominal other assets.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on pages 15,
149 and 361 of the First Amended Registration Statement in response to the Staff's comment.

 Agreements Related to the Merger

 Lock-Up Agreements, page 151

 14. You state that the Crescent stockholders who have executed lock-up agreements as of February 7,
2025 owned, in the aggregate, approximately 98.5% of the shares of Crescent's outstanding capital stock. Please also disclose the
percentage of shares you expect to be subject to the lock-up agreements on a fully diluted basis immediately following consummation of
the merger.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on page 171
of the First Amended Registration Statement in response to the Staff's comment.

 Subscription Agreement, page 151

 15. To the extent not already described in this section, please revise your disclosure to briefly describe
the material terms of the pre-funded warrants to be issued in connection with the merger transactions, including, for example, the exercise
price and duration of the warrants.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on pages
171 and 172 of the First Amended Registration Statement in response to the Staff's comment.

 Consulting Agreements and Offer Letters,
page 172

 16. Please disclose the term of Crescent's consulting agreement and offer letter with Dr. Violin
and Mr. Doughty, respectively. In addition, given Dr. Violin's affiliation with Fairmount and the fact that Dr. Violin
does not appear to be an employee of Crescent, please briefly describe any potential conflicts of interest or other risks that may arise
in connection with Dr. Violin's consulting arrangement with Crescent, and to the extent material, include appropriate risk
factor disclosure regarding the same.

 Response :
The Company respectfully acknowledges the Staff's comment and advises the Staff that it has revised the disclosure on
pages 193, 195 and 196 of the First Amended Registration Statement in response to the Staff's comment. The Company
respectfully advises the Staff that, effective as of March 17, 2025, Crescent replaced Dr. Violin as its Chief Executive
Officer with an individual not affiliated with Fairmount, and Dr. Violin's consulting agreement terminated effective
March 31, 2025.

 Securities and Exchange
Commission

 April 4, 2025

 Page 7

 Matters Being S